Accurate diagnosis and precise characterization of uterine fibroids are fundamental to treatment planning. While Transvaginal Ultrasound remains the initial, first-line imaging modality due to its accessibility, Magnetic Resonance Imaging (MRI) is increasingly recognized as the definitive tool for complex cases. MRI provides superior visualization for determining the exact number, size, and location of fibroids, and is crucial for ruling out mimics like adenomyosis or sarcoma.

Treatment planning is standardized globally by the FIGO (International Federation of Gynecology and Obstetrics) Classification System. This system categorizes fibroids from Type 0 to Type 8 based on their relationship to the uterine wall and endometrial cavity. For instance, submucosal fibroids (Types 0-2) are typically treated by hysteroscopy, whereas intramural (Types 3-5) and subserosal (Types 6-8) fibroids often necessitate laparoscopic or interventional procedures. The consistent use of this classification, supported by high-resolution imaging, is vital for minimizing surgical risk and improving procedural success in the Uterine Fibroid Market, as detailed in clinical imaging guidelines, such as the Uterine Fibroid Market Global Outlook.